Previous 10 | Next 10 |
home / stock / agnpf / agnpf news
VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Mark ...
VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans t...
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that its CEO Ch...
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has con...
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- Microdose Psychedelic Insights , a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, w...
VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that...
VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atossa Therapeutics (NASDAQ: ATOS ) is a highly intriguing company that has a great deal of potential. I recommend, however, that investors avoid taking a bullish position in ATOS stock for now. Source: CI Photos /...
Algernon Pharmaceuticals (AGNPF) has reached 70% of its enrollment target for its Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis ((IPF)) and chronic cough.The 20-patient proof-of-concept trial aims to determine the efficacy of Ifenpro...
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, announces that it has reach...
News, Short Squeeze, Breakout and More Instantly...
Algernon Pharmaceuticals Inc - Class A Company Name:
AGNPF Stock Symbol:
OTCMKTS Market:
Algernon Pharmaceuticals Inc - Class A Website:
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report that ifenprodil achieved...
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its...